Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Genetic risk prediction: individualized variability in susceptibility to toxicants.

Nebert DW, Zhang G, Vesell ES.

Annu Rev Pharmacol Toxicol. 2013;53:355-75. doi: 10.1146/annurev-pharmtox-011112-140241. Review.

PMID:
23294311
2.

Safety issues of maternal drug therapy during breastfeeding.

Berlin CM Jr, Paul IM, Vesell ES.

Clin Pharmacol Ther. 2009 Jan;85(1):20-2. doi: 10.1038/clpt.2008.209.

PMID:
19092767
3.

Declines in NIH R01 research grant funding.

Mandel HG, Vesell ES.

Science. 2008 Oct 10;322(5899):189. doi: 10.1126/science.322.5899.189a. No abstract available.

PMID:
18845728
4.

From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Nebert DW, Zhang G, Vesell ES.

Drug Metab Rev. 2008;40(2):187-224. doi: 10.1080/03602530801952864 . Review.

5.

Pharmacology and statistics: recommendations to strengthen a productive partnership.

Spector R, Vesell ES.

Pharmacology. 2006;78(3):113-22. Epub 2006 Sep 27.

6.

Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics.

Nebert DW, Vesell ES.

Trends Pharmacol Sci. 2006 Nov;27(11):580-6. Epub 2006 Sep 26. Erratum in: Trends Pharmacol Sci. 2007 Feb;28(2):50.

PMID:
17005258
7.

Declines in funding of NIH R01 research grants.

Mandel HG, Vesell ES.

Science. 2006 Sep 8;313(5792):1387-8. No abstract available.

PMID:
16959989
8.

The heart of drug discovery and development: rational target selection.

Spector R, Vesell ES.

Pharmacology. 2006;77(2):85-92. Epub 2006 May 5.

9.

The power of pharmacological sciences: the example of proton pump inhibitors.

Spector R, Vesell ES.

Pharmacology. 2006;76(3):148-55; discussion 156. Epub 2006 Feb 1.

10.

From progress to regression: biomedical research funding.

Mandel HG, Vesell ES.

J Clin Invest. 2004 Oct;114(7):872-6. Erratum in: J Clin Invest. 2004 Dec;114(11):1687.

11.

Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead.

Nebert DW, Vesell ES.

Eur J Pharmacol. 2004 Oct 1;500(1-3):267-80. Review. Erratum in: Eur J Pharmacol. 2005 Jan 4;506(3):297.

PMID:
15464039
12.

Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements.

Nebert DW, Jorge-Nebert L, Vesell ES.

Am J Pharmacogenomics. 2003;3(6):361-70. Review.

PMID:
14672516
13.

Recollections from the Kunkel laboratory, 1956-1958.

Vesell ES.

Lupus. 2003;12(3):238-41.

PMID:
12708789
14.

Which studies of therapy merit credence? Vitamin E and estrogen therapy as cautionary examples.

Spector R, Vesell ES.

J Clin Pharmacol. 2002 Sep;42(9):955-62. Review.

PMID:
12211220
15.

A rational approach to the selection of useful drugs for clinical practice.

Spector R, Vesell ES.

Pharmacology. 2002 May;65(2):57-61.

PMID:
11937774
16.

NIH budget grows, but not R01 success rates.

Mandel HG, Vesell ES.

Science. 2001 Oct 5;294(5540):54-7. No abstract available.

PMID:
11589231
17.

The pursuit of clinical truth: role of epidemiology/observation studies.

Spector R, Vesell ES.

J Clin Pharmacol. 2000 Nov;40(11):1205-10.

PMID:
11075306
18.

Advances in pharmacogenetics and pharmacogenomics.

Vesell ES.

J Clin Pharmacol. 2000 Sep;40(9):930-8. Review.

PMID:
10975065
19.

Introduction

Vesell ES.

Pharmacology. 2000 Sep;61(3):118-23. No abstract available.

PMID:
10971197
21.

Are the elderly underrepresented in clinical drug trials?

Schmucker DL, Vesell ES.

J Clin Pharmacol. 1999 Nov;39(11):1103-8. Review.

PMID:
10579140
22.

Likelihood of NIH extramural funding.

Mandel HG, Vesell ES.

Science. 1999 Sep 10;285(5434):1674-6. No abstract available.

PMID:
10523182
23.

Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in rhesus monkeys.

Meger M, Richter E, Zwickenpflug W, Oehlmann C, Hargaden MB, A-Rahim YI, Vesell ES.

Drug Metab Dispos. 1999 Apr;27(4):471-8.

PMID:
10101142
24.

Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects.

Vesell ES, Beyer KH Jr.

Pharmacology. 1999 Mar;58(3):140-6.

PMID:
9925970
25.

Genetic variation as a guide to drug development.

Kleyn PW, Vesell ES.

Science. 1998 Sep 18;281(5384):1820-1. No abstract available.

PMID:
9776686
26.

Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study.

Ahsan N, Korsunsky Z, Beyer KH Jr, Vesell ES.

Pharmacology. 1998 Aug;57(2):96-103.

PMID:
9691229
27.
28.

Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats.

Follansbee MH, Beyer KH Jr, Vesell ES.

Pharmacology. 1997 May;54(5):256-60.

PMID:
9380771
29.

Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.

Follansbee MH, Beyer KH Jr, Griffith JW, Vesell ES.

Pharmacology. 1997 May;54(5):241-55.

PMID:
9380770
30.

Therapeutic lessons from pharmacogenetics.

Vesell ES.

Ann Intern Med. 1997 Apr 15;126(8):653-5. No abstract available.

PMID:
9103135
31.

Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging.

Korrapati MR, Sorkin JD, Andres R, Muller DC, Loi CM, Vesell ES, Vestal RE.

J Clin Pharmacol. 1997 Feb;37(2):83-91.

PMID:
9055133
32.

Reflections from distant cuvettes.

Vesell ES.

Drug Metab Rev. 1996 Nov;28(4):493-511. Review.

PMID:
8959389
34.

Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes.

A-Rahim YI, Beyer KH Jr, Vesell ES.

Pharmacology. 1996 Oct;53(4):197-210.

PMID:
8958558
35.
36.

Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats.

A-Rahim YI, Beyer KH Jr, Vesell ES.

Pharmacology. 1996 Mar;52(3):135-44.

PMID:
8849482
37.

Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe.

Vesell ES, Seaton TD, A-Rahim YI.

Pharmacogenetics. 1995 Feb;5(1):53-7. No abstract available.

PMID:
7773304
38.

Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods.

Vesell ES, Gaylor DW.

Pharmacogenetics. 1995 Feb;5(1):18-23. No abstract available.

PMID:
7773299
39.

Women in clinical drug trials. An update.

Schmucker DL, O'Mahony MS, Vesell ES.

Clin Pharmacokinet. 1994 Dec;27(6):411-7. Review. No abstract available.

PMID:
7882633
40.

Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients.

Vesell ES, Chambers CE, Seaton TD, Passananti GT, Demers LM, Beyer KH Jr.

J Clin Pharmacol. 1994 Dec;34(12):1234-45.

PMID:
7738221
41.

Nicotine metabolism in cigarette smokers and nonsmokers.

Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES.

Clin Pharmacol Ther. 1994 Jan;55(1):84-7. No abstract available.

PMID:
8299321
42.

Basal and paracetamol-depleted glutathione from human lymphocytes: ethnic variability.

Estévez F, De Angelo T, Vesell ES.

Acta Physiol Pharmacol Ther Latinoam. 1994;44(1-2):48-54.

PMID:
7640405
43.

Variables affecting nicotine metabolism.

Seaton MJ, Vesell ES.

Pharmacol Ther. 1993 Dec;60(3):461-500. Review.

PMID:
8073071
45.

Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus.

Vesell ES, Chambers CE, Passananti GT, Demers LM, Beyer KH Jr.

J Clin Pharmacol. 1993 Sep;33(9):823-31.

PMID:
8227479
46.

Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile.

Seaton MJ, Kyerematen GA, Vesell ES.

Drug Metab Dispos. 1993 Sep-Oct;21(5):927-32.

PMID:
7902257
47.

Reproducibility of antipyrine half-lives in elderly subjects.

Vesell ES, DeAngelo TM, Katz IR.

Clin Pharmacol Ther. 1993 Aug;54(2):150-7.

PMID:
8354024
48.

Underrepresentation of women in clinical drug trials.

Schmucker DL, Vesell ES.

Clin Pharmacol Ther. 1993 Jul;54(1):11-5. No abstract available.

PMID:
8330458
49.

Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency.

Beyer KH Jr, Ward TD, Vary JE, Gelarden RT, Knutson DW, Vesell ES.

J Clin Pharmacol. 1993 Jun;33(6):554-61.

PMID:
8366180
50.

Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects.

Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH Jr.

J Clin Pharmacol. 1992 Dec;32(12):1128-34.

PMID:
1487552

Supplemental Content

Loading ...
Support Center